Market open · Delayed intraday data · 2:12 PM ET
Last update: Aug 10, 2026, 2:03 PM ET
Alnylam Pharmaceuticals, Inc.
$218.23 0.44% today
Market Open

Why Alnylam Pharmaceuticals, Inc. (ALNY) stock moved

Updated Aug 10, 2026

Alnylam Pharmaceuticals, Inc. (ALNY) shares fell 0.4% to $218.23 as of August 10, 2026, a slight decline from the prior close of $219.20. BestStocks flagged the session as a major change for ALNY. The move is tied to price move down. Below, we break down what changed for ALNY, why it matters for investors, how the stock reacted, and the catalysts on the calendar.

What happened

ALNY fell 0.4% to $218.23

ALNY fell 0.4% in its latest session, moving from $219.20 to $218.23.

Material / EarningsWeak confidence
Rel. volume
0.4×
Below Avg
Vs peers
No comparable peers
Market cap
$29.2B
NASDAQ Global Select
Analyst target
$387
+77.4% vs price
Price chart
Jul 10 – Aug 10
EVVEEVEVFVVV$205$252$299Jul 10Jul 17Jul 27Aug 3Aug 10
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details

What it means for Alnylam Pharmaceuticals, Inc. investors

For Alnylam Pharmaceuticals, Inc. investors, the recent signals add up to a strong bearish shift. On the constructive side: ALNY moved +2.73% from $313.04 to $321.59 on 2026-07-07. Weighing against that: Material negative event; Negative session, down 0.4%. Wall Street's consensus price target sits at $387.18, implying +77.4% upside from $218.23. BestStocks rates the overall signal quality weak (30/100). With earnings roughly 80 days out, the next report is the most likely near-term test of the move.

ALNY price reaction

ALNY last traded at $218.23, down $0.97 (-0.44%) from the previous close of $219.20. The session traded on 0.4× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $205.48 and $298.76, and it currently sits about 14% of the way up that band.

Bullish and bearish analyst opinions on Alnylam Pharmaceuticals, Inc. (ALNY)

The consensus analyst price target on Alnylam Pharmaceuticals, Inc. (ALNY) is $387.18, 77.4% above the recent $218.23. Over the past 90 days analysts logged 0 upgrades, 15 maintains, and 0 downgrades. Here is how the bullish and bearish cases on ALNY line up.

The bullish case

  • Wall Street's consensus price target of $387.18 implies +77.4% upside from $218.23.
  • The Street's most bullish target is $455.00 (+108.5%).
  • ALNY moved +2.73% from $313.04 to $321.59 on 2026-07-07.

The bearish case

  • Material negative event.
  • Negative session, down 0.4%.
  • Alnylam Pharmaceuticals plummeted 27.66% to $207.34 following an earnings report and material event filing (8-K) released today.
Bull vs bear balanceStrong Bearish Shift
BearishNeutralBullish

Weighing both sides, BestStocks' composite read of recent signals is strongly bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.

Analyst price targets and ratings are FMP consensus figures as of Aug 10, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.

Analyst expectations
Consensus target: $387+77.4%
= 15 maintains
RBC Capital maintained Outperform · 2026-07-31
SEC filings watch
10-Q2026-07-30
Quarterly financial results
medium
8-K2026-07-30
Material event — review for impact
high
8-K2026-05-27
Material event — review for impact
high
8-K2026-04-30
Material event — review for impact
high
Peer context
ALNY-0.4%

Previous notable changes for ALNY

Material / Earnings2026-08-05+4.4%
Alnylam Pharmaceuticals, Inc. (ALNY) moved +3.15% from $221.74 to $228.72 on 2026-08-05. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was near its 5-day average, suggesting the move was not driven by unusual trading activity.
Valuation2026-08-03+7.2%via investing.com
Alnylam Pharmaceuticals rose 6.53% to $218.94 intraday on August 3, 2026. The evidence cites investing.com as a source for the move but does not specify the underlying catalyst. Volume of 2.24M shares is running 1.12x the historical average at this time of day, suggesting normal trading flow rather than unusual accumulation.
Valuation2026-07-31+0.0%via Yahoo Finance
Alnylam reported Q2 revenue of $1.29 billion, missing consensus estimates of $1.32 billion, and lowered full-year TTR net product revenue guidance citing normalization in Amvuttra demand. Wells Fargo and other major analysts cut price targets (Wells Fargo reduced from $377 to $316) in response to the top-line miss and cautious outlook on the cardiomyopathy indication ramp. Stock declined 2.11% to $201.15 on elevated volume (2.04x average for the time of day).
Risk2026-07-30-28.3%
Alnylam Pharmaceuticals plummeted 27.66% to $207.34 following an earnings report and material event filing (8-K) released today. Volume surged to 2.3M shares, trading at nearly 10x the expected level for this point in the session, signaling sharp institutional repositioning around the disclosed developments.
Upcoming catalysts & outlook
Next earnings
2026-10-29 (est.)
in 80 days
Thesis shift
Strong Bearish Shift
bearish signal
Risk level
High
from change events

Frequently asked questions about ALNY

Why did Alnylam Pharmaceuticals, Inc. (ALNY) stock move?

ALNY fell 0.4% to $218.23. No single company-specific catalyst was confirmed during the move window, and it looks technical.

How much did ALNY stock fall?

ALNY lost 0.44% ($0.97) versus the prior close of $219.20, last trading at $218.23 on 0.4× average volume.

When is Alnylam Pharmaceuticals, Inc.'s next earnings date?

ALNY's next earnings report is estimated for 2026-10-29 — about 80 days away.

What is the analyst price target for ALNY?

The consensus analyst price target for ALNY is $387.18, about 77.4% above the current $218.23. Over the past 90 days, analysts recorded 0 upgrades, 15 maintains, and 0 downgrades.

How BestStocks tracks ALNY

This page is generated automatically by BestStocks' change-detection system after price move down was detected and verified against independent data sources. It draws on 20 tracked change events for ALNY, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of August 10, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.

Data sources
FMP real-time & historical price dataFMP earnings & estimatesSEC EDGAR filingsAnalyst ratings & price targets (FMP)Earnings calendar (FMP)
Educational research tool — not personalized investment advice. Data may be delayed.